C
에이프로젠
007460KOSPI50.0 / 100
Reference Date: 2026-10-23
Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 3.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Aprogen operates major businesses in hardfacing, steel sales, nuclear insulation, pharmaceuticals, and biopharmaceuticals, maintaining a leading position in the domestic hardfacing market. The biopharmaceutical division focuses on developing biosimilars and new drugs, successfully selling Remicade biosimilars in the Japanese market.
Number of Employees
311people
Average Salary
52.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.11Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
-31.28Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
16.33Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼10.9% (2-year basis)
Operating Profit Growth Rate
0.5 / 3
Avg ▼3.9% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -25.6% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (25%)
Current 1,903Won52-week high 6,76052-week low 280
1-month return2.0Point
1m -3.40% (slight drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-08
- Neutral타인에대한담보제공결정(자회사의 주요경영사항)2026-10-08